Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Propensity score-matched analysis comparing robot-assisted partial nephrectomy and image-guided percutaneous cryoablation for cT1 renal cell carcinoma.
Yamanoi T, Bekku K, Yoshinaga K, Maruyama Y, Nagao K, Kawada T, Tominaga Y, Umakoshi N, Sadahira T, Katayama S, Iwata T, Uka M, Nishimura S, Edamura K, Kobayashi T, Kobayashi Y, Hiraki T, Araki M. Yamanoi T, et al. Urol Oncol. 2024 Dec;42(12):453.e15-453.e22. doi: 10.1016/j.urolonc.2024.09.012. Epub 2024 Oct 5. Urol Oncol. 2024. PMID: 39368943
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
Yanagisawa T, Mori K, Kawada T, Katayama S, Uchimoto T, Tsujino T, Nishimura K, Adachi T, Toyoda S, Nukaya T, Fukuokaya W, Urabe F, Murakami M, Yamanoi T, Bekku K, Komura K, Takahara K, Hashimoto T, Fujita K, Azuma H, Ohno Y, Shiroki R, Uemura H, Araki M, Kimura T; JK-FOOT study group. Yanagisawa T, et al. Among authors: yamanoi t. Urol Oncol. 2024 Nov;42(11):374.e21-374.e29. doi: 10.1016/j.urolonc.2024.06.013. Epub 2024 Jul 31. Urol Oncol. 2024. PMID: 39085019
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S, Iwata T, Kawada T, Okamoto Y, Sano Y, Kawago Y, Miyake S, Moriwake T, Kuinose A, Horikawa Y, Tsuboi K, Tsuboi I, Sakaeda K, Nakatsuka H, Takamoto A, Hirata T, Shirasaki Y, Yamasaki T, Morinaka H, Nagasaki N, Hara T, Ochi A, Okumura M, Watanabe T, Sekito T, Kawano K, Horii S, Yamanoi T, Nagao K, Yoshinaga K, Maruyama Y, Tominaga Y, Sadahira T, Nishimura S, Edamura K, Kobayashi T, Kusumi N, Kurose K, Yamamoto Y, Sugimoto M, Nakada T, Sasaki K, Takenaka T, Ebara S, Miyaji Y, Wada K, Kobayashi Y, Araki M. Katayama S, et al. Among authors: yamanoi t. Urol Oncol. 2024 Mar;42(3):70.e11-70.e18. doi: 10.1016/j.urolonc.2023.11.009. Epub 2023 Dec 20. Urol Oncol. 2024. PMID: 38129282
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
Sekito T, Bekku K, Katayama S, Watanabe T, Tsuboi I, Yoshinaga K, Maruyama Y, Yamanoi T, Kawada T, Tominaga Y, Sadahira T, Iwata T, Nishimura S, Kusumi N, Edamura K, Kobayashi T, Kurose K, Ichikawa T, Miyaji Y, Wada K, Kobayashi Y, Araki M. Sekito T, et al. Among authors: yamanoi t. Clin Genitourin Cancer. 2024 Aug;22(4):102097. doi: 10.1016/j.clgc.2024.102097. Epub 2024 Apr 17. Clin Genitourin Cancer. 2024. PMID: 38763123
Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.
Sadahira T, Wada K, Araki M, Ishii A, Takamoto A, Kobayashi Y, Watanabe M, Watanabe T, Nasu Y, Kumon H; Okayama Urological Research Group (OURG). Sadahira T, et al. J Antimicrob Chemother. 2017 Feb;72(2):529-534. doi: 10.1093/jac/dkw424. Epub 2016 Oct 12. J Antimicrob Chemother. 2017. PMID: 27733519 Free article. Clinical Trial.
55 results